PPA
ORMP icon

Parametric Portfolio Associates’s Oramed Pharmaceuticals ORMP Stock Holding History

Parametric Portfolio Associates’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-11,764
Closed -$168K – 3740
2021
Q4 		$168K Buy
+11,764
New +$246K ﹤0.01% 3457

Other funds holding ORMP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return

Parametric Portfolio Associates's ORMP Position: Q1 2022 in Review

Parametric Portfolio Associates sold out of Oramed Pharmaceuticals (ORMP) in Q1 2022, closing a stake of 11,764 shares — an estimated $168K sold.

Parametric Portfolio Associates first reported a position in ORMP in Q4 2021 and held it in 1 quarter. The position peaked at $168K in Q4 2021. 103 funds tracked by Wall St. Rank hold ORMP as of Q1 2022.

  • Parametric Portfolio Associates reported no remaining Oramed Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Parametric Portfolio Associates sold 11,764 Oramed Pharmaceuticals shares in Q1 2022, an estimated $168K.
  • Parametric Portfolio Associates first reported a position in Oramed Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Parametric Portfolio Associates's Oramed Pharmaceuticals position peaked at $168K in Q4 2021.
  • 103 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.